The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions

P-glycoprotein (PGP) is well known because of its contribution to multiple-drug resistance during anticancer treatment. More recent work indicates that PGP mediates the transcellular transport of many drugs in addition to anticancer compounds. Because of this reason, its potential role in clinically significant drug-drug interactions has just begun to be realized. This article provides an overview of published in vitro, in situ, and in vivo drug-drug interaction results that are related to PGP transport so that the awareness of the scientific community can be heightened. In addition, several recommendations are made to take full advantage of the recently published data.

This article has been cited by other articles:

				S. Vaidyanathan, G. Camenisch, H. Schuetz, C. Reynolds, C.-M. Yeh, M.-N. Bizot, H. A. Dieterich, D. Howard, and W. P. Dole Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P-Glycoprotein in the Disposition of Aliskiren J. Clin. Pharmacol., November 1, 2008; 48(11): 1323 - 1338. [Abstract] [Full Text] [PDF]

				U. G. Eriksson, H. Dorani, J. Karlsson, H. Fritsch, K.-J. Hoffmann, L. Olsson, T. C. Sarich, U. Wall, and K.-M. Schutzer INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION Drug Metab. Dispos., May 1, 2006; 34(5): 775 - 782. [Abstract] [Full Text] [PDF]

				N. Nishio, T. Katsura, K. Ashida, M. Okuda, and K.-i. Inui MODULATION OF P-GLYCOPROTEIN EXPRESSION IN HYPERTHYROID RAT TISSUES Drug Metab. Dispos., November 1, 2005; 33(11): 1584 - 1587. [Abstract] [Full Text] [PDF]

				R. L. Page II, P. M Klem, and C. Rogers Potential Elevation of Tacrolimus Trough Concentrations with Concomitant Metronidazole Therapy Ann. Pharmacother., June 1, 2005; 39(6): 1109 - 1113. [Abstract] [Full Text] [PDF]

				K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF]

				C. S. Karyekar, N. D. Eddington, A. Briglia, P. O. Gubbins, and T. C. Dowling Renal Interaction Between Itraconazole and Cimetidine J. Clin. Pharmacol., August 1, 2004; 44(8): 919 - 927. [Abstract] [Full Text] [PDF]

				S. Zhou, E. Chan, S.-Q. Pan, M. Huang, and E. J. D. Lee Pharmacokinetic Interactions of Drugs with St John's Wort J Psychopharmacol, June 1, 2004; 18(2): 262 - 276. [Abstract] [PDF]

				J. Weiss, C. J. Kerpen, H. Lindenmaier, S.-M. G. Dormann, and W. E. Haefeli Interaction of Antiepileptic Drugs with Human P-Glycoprotein in Vitro J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 262 - 267. [Abstract] [Full Text] [PDF]

				N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF]

				C. Aleman, J.-P. Annereau, X.-J. Liang, C. O. Cardarelli, B. Taylor, J. J. Yin, A. Aszalos, and M. M. Gottesman P-Glycoprotein, Expressed in Multidrug Resistant Cells, Is Not Responsible for Alterations in Membrane Fluidity or Membrane Potential Cancer Res., June 15, 2003; 63(12): 3084 - 3091. [Abstract] [Full Text] [PDF]

				S. C. Armstrong and K. L. Cozza Pharmacokinetic Drug Interactions of Morphine, Codeine, and Their Derivatives: Theory and Clinical Reality, Part I Psychosomatics, April 1, 2003; 44(2): 167 - 171. [Abstract] [Full Text] [PDF]

				J. Weiss, S.-M. G. Dormann, M. Martin-Facklam, C. J. Kerpen, N. Ketabi-Kiyanvash, and W. E. Haefeli Inhibition of P-Glycoprotein by Newer Antidepressants J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 197 - 204. [Abstract] [Full Text]

				C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. Marz, J. P. D. Reckless, and E. A. Stein Risk for Myopathy With Statin Therapy in High-Risk Patients Arch Intern Med, March 10, 2003; 163(5): 553 - 564. [Abstract] [Full Text] [PDF]

				S. Zhang and M. E. Morris Effects of the Flavonoids Biochanin A, Morin, Phloretin, and Silymarin on P-Glycoprotein-Mediated Transport J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1258 - 1267. [Abstract] [Full Text] [PDF]

				E. Ernst St John's Wort Supplements Endanger the Success of Organ Transplantation Arch Surg, March 1, 2002; 137(3): 316 - 319. [Abstract] [Full Text] [PDF]

				J. G. Sarver, W. A. Klis, J. P. Byers, and P. W. Erhardt Microplate Screening of the Differential Effects of Test Agents on Hoechst 33342, Rhodamine 123, and Rhodamine 6G Accumulation in Breast Cancer Cells that Overexpress P-Glycoprotein J Biomol Screen, February 1, 2002; 7(1): 29 - 34. [Abstract] [PDF]

				M. Yamazaki, W. E. Neway, T. Ohe, I-W. Chen, J. F. Rowe, J. H. Hochman, M. Chiba, and J. H. Lin In Vitro Substrate Identification Studies for P-glycoprotein-Mediated Transport: Species Difference and Predictability of in Vivo Results J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 723 - 735. [Abstract] [Full Text]

				K. W. Ward, J. W. Proksch, M. A. Levy, and B. R. Smith Development of an in Vivo Preclinical Screen Model to Estimate Absorption and Bioavailability of Xenobiotics Drug Metab. Dispos., January 1, 2001; 29(1): 82 - 88. [Abstract] [Full Text]

				S. Ibrahim, J. Peggins, A. Knapton, T. Licht, and A. Aszalos Influence of Antipsychotic, Antiemetic, and Ca2+ Channel Blocker Drugs on the Cellular Accumulation of the Anticancer Drug Daunorubicin: P-glycoprotein Modulation J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1276 - 1283. [Abstract] [Full Text]

				T. O. Cheng St John's Wort Interaction With Digoxin Arch Intern Med, September 11, 2000; 160(16): 2548 - 2548. [Full Text]